AJY declares grants and contracts paid to their institution from Medtronic, Cerenovus, Penumbra, Stryker, Genentech, Balt, and Route 92; consulting fees from Penumbra, Vesalio, and NIH/NINDS; participation on a data safety and monitoring board or advisory board with Route 92 and HCA Neurovascular Research Advisory Board; and stock or stock options in Insera Therapeutics, Galaxy Medical, Gravity Medical, and Nicolab. AEH declares consulting fees from Medtronic, Microvention, Stryker, Penumbra, J&J MedTech, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Insera therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, Rapid Medical, Imperative Care, Galaxy Therapeutics, Route 92, Perfuze, CorTech, Imago, Shockwave, Toro, NeuroVasX, Xcath, Kaneka, Plaga, Project Neu, Piraeus, BioPhiliQ, Arbor Medical, Medinol, Navigantis, and Magnisity; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medtronic, Microvention, Stryker, Penumbra, J&J MedTech, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Insera therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, Rapid Medical, Imperative Care, Galaxy Therapeutics, Route 92, Perfuze, CorTech, Imago, Shockwave, Toro, NeuroVasX, Xcath, Kaneka, Plaga, Project Neu, Piraeus, BioPhiliQ, Arbor Medical, Medinol, Navigantis, and Magnisity; participation on a data safety and monitoring board for the COMAND trial and FOCUS trial; and being Past President of the Society of Vascular and Interventional Neurology. AS declares grant support as a global principal investigator (PI) for SELECT LATE (Patient-Centered Outcomes Research Institute; paid to their institution) and as a PI for SELECT, SELECT2, and Stryker Neurovascular (paid to their institution). AR declares consulting fees from Stryker NV, Cerenovous, Route 92; and participation on a data safety and monitoring board for ATHENA and TORNADO. BG declares grant support from the French Ministry of Health as a PI for TITAN, DIRECT ANGIO, and IA-SUCCESS; consulting fees from Air Liquide, MIVI, Medtronic, Microvention, Perfuze, and Penumbra; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Acticor Biotech, Medtronic, and Penumbra. BL declares grants or contracts from Balt, Microvention, and Phenox; and consulting fees from Olea Medical. CA declares consulting fees from Medtronic; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Medtronic. CM declares grants or contracts from the European Union, CVON/Dutch Heart Foundation, Boehringer Ingelheim, and Stryker (paid to their institution); and stock or stock options from Nicolab (minority interest). CZS declares grants or contracts from the Health Research Foundation of Central Denmark Region (research grant from hospital); and participation on a data safety monitoring board or advisory board for EAST-STROKE. DSL declares consulting fees for imaging core laboratory work from Johnson & Johnson and Rapid Medical. DD declares participation on a data and safety monitoring committee for ACT Global, and, in the past, data and safety monitoring committee for TESLA; and role as Vice Chair of the data access committee of CONTRAST consortium. GM declares consulting fees from Stryker, Terumo Neuro, and Sim & Cure; payment for lectures for Penumbra, Medtronic, Wallaby Phenox, Cerenovus (Johnson & Johnson), and Bracco; and participation on an advisory board for the MAESTRO study. GT declares (related to the current manuscript) receipt of funding for the TENSION trial from the EU Horizon 2020 Research and Innovation Programme under grant agreement number 754640; consulting fees from Acandis, Bayer, Boehringer Ingelheim, and TarGED; payment or honoraria from Acandis, Boehringer Ingelheim, and Lilly; and role as Chair of the Board of Directors of the European Stroke Organisation. HY declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Daiichi-Sankyo, Otsuka Pharmaceutical, Stryker, Boston Scientific, Abbott Medical (lecture fee, personal). JCG declares research grants from Genentech (supplies investigational product); consulting fees from Frazer (consulting on mobile stroke unit); payment for expert testimony from various law firms (legal malpractice cases) three times in 2026; support for attending meetings and/or travel from Perosphere (consulting meeting); participation as chair of a data safety monitoring board for Prolong Pharma. JF declares, for the current project, role as managing director of EppData (completed imaging core laboratory work for TENSION trial); consulting fees (personal) from Medtronic, Stryker, Microvention/Terumo, Cerenovus/JuJ Medtech, Acandis, Phenox, and Penumbra; support for attending meetings and/or travel from Microport; participation on a data safety monitoring board or advisory board for Stryker and Phenox; role as Past President of ESMINT; and stock or stock options for Eppdata and Vastrax. MJ declares consulting fees for advisory boards for BMS and Bayer. MB declares grants from EU Horizon 2020 for the TENSION trial, the EU for the VALIDATE trial, and the DFG for SFB project C02; payment or honoraria for educational talks for Novartis and Boehringer Ingelheim; and role as Editor in Chief for Clinical Neuroradiology (Springer). MC declares consulting fees from RapidPulse and Route 92; payment for expert testimony from various law firms; participation on a data safety monitoring board or advisory board for STEM; and role as Editor of Journal of NeuroInterventional Surgery. MDH declares grants or contracts from NoNO (grant to the University of Calgary for the ESCAPE-NA1 trial, ESCAPE NEXT trial), Canadian Institutes for Health Research (grant to the University of Calgary for the ESCAPE-NA1 trial, ESCAPE NEXT trial, and ACT-GLOBAL trial), Medtronic (grant to the University of Calgary for the ESCAPE-MeVO study), and Boehringer Ingelheim (grant to the University of Calgary for ACT-GLOBAL trials); consulting fees from Sun Pharma (for adjudication of clinical trials outcomes); patents planned, issued, or pending (US Patent 62/086,077, licensed to Circle NVI; and US Patent 10 916,346, licensed to Circle NVI); participation as data and safety monitoring committee chair for ONCOVIR Hiltonel trial, DUMAS trial, EMAGINE trial, EVERLAST trial, ILLUMINATE trial, and POTENTIAL trial; participation as data safety monitoring board member for the ARTESIA trial, BRAIN-AF trial, and LAOOS trial; role as President of the Canadian Neurological Sciences Federation (not for profit); stock or stock options in Circle Inc and Basking Biosciences (private stock or stock options). RG declares consulting fees from Medtronic, Balt, Cerenovus, Kaneka, and Stryker Neurovascular. SY declares payment or honoraria for lectures from Daiichi Sankyo, Bristol Myers Squibb, Otsuka Pharmaceutical, Stryker, Medtronic, Johnson & Johnson, Kaneka Medics, Terumo, Medicos Hirata, Nxera Pharma, and Eisai. SAS declares consulting fees (personal) from Penumbra, Route 92, Perfuze, Balt, and Kaneka; support for attending meetings and/or travel from the American Heart Association and the German Neuroradiology Society; and participation on a data safety monitoring board or advisory board for Vesalio (clinical events committee participation). SBo declares funding for the present manuscript from EU Horizon 2020 and EU Horizon 2.1. TM declares other financial interests, outside the submitted work, in Abbott, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, GlaxoSmithKline, Integra LifeSciences, Pfizer, UCB, Japan Lifeline. TGJ declares grants or contracts from NIH (STEP), PCORI, and Stryker; consulting fees from Medtronic, Johnson & Johnson, and Contego Medical; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Medtronic; participation on a data safety monitoring board or advisory board for Johnson and Johnson; and stock or stock options in Route 92, Viz.ai, Methinks, Gravity, Galaxy, Anaconda, Kandu, FreeOx Biotech, and Vastrax. WS declares participation on a data safety monitoring board for the PICASSO Trial, SEGA Trial, TESLA Trial, TESSERACT-2 Trial, and role as safety adjudicator for the SISTER trial. RGN reports research grants from Cerenovus and Stryker Neurovascular to the University of Pittsburgh; role as a principal investigator of the “Endovascular Therapy for Low NIHSS Ischemic Strokes (ENDOLOW)” trial (funding provided by Cerenovus); role as a principal investigator of the “Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe (DUSK)” trial (funding provided by Stryker Neurovascular); consulting fees for advisory roles with Anaconda, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, J&J, Cerenovus, Genentech, Philips, Hybernia, Hyperfine, Imperative Care, Medtronic, Merck, Phenox, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, Synchron, Takeda Pharmaceutical; stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, CrestecBio, Euphrates Vascular, Vesalio, Viz.ai, RapidPulse, Sensome, and Perfuze; and being an investor in Viz.ai, Perfuze, Cerebrotech, Reist/Q’Apel Medical, Truvic, Tulavi Therapeutics, Vastrax, Piraeus Medical, Brain4Care, Quantanosis AI, Unity Medical, and Viseon. SOG reports research grants from NIH/NINDS, PCORI, Stryker, Medtronic, and Methinks; consulting fees from Stryker and Medtronic; payment or honoraria from Stryker and Medtronic; appointment as president of the Society of Vascular and Interventional Neurology; and stock options and equity in Motif, Gravity, and Clotter. TNN reports consulting fees as an advisor for Bayer, Route 92, and Medtronic; and appointment as Associate Editor for Stroke. All other authors declare no competing interests.
